SCHEMBL4375533

SCHEMBL4375533

COc1cc2c(Oc3cc4cc[nH]c4cc3F)ncnc2cc1OCCCN1CCN(C)CC1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 12/20 0.61
FLT4 P35916 9/20 0.61
PDGFRB P09619 4/20 0.61
TEK Q02763 4/20 0.61
AURKB Q96GD4 4/20 0.61
AURKA O14965 3/20 0.61
FLT1 P17948 6/20 0.57
EGFR P00533 6/20 0.57
FGFR1 P11362 4/20 0.57
RET P07949 3/20 0.57
SRC P12931 3/20 0.57
MET P08581 3/20 0.57
PLK4 O00444 1/20 0.57
GAK O14976 1/20 0.57
EPHB6 O15197 1/20 0.57
RIPK2 O43353 1/20 0.57
ERN1 O75460 1/20 0.57
STK10 O94804 1/20 0.57
MAP4K4 O95819 1/20 0.57
CHEK2 O96017 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3193673 0.94 KDR (0.65) KDRFLT4PDGFRBTEKAURKB
SCHEMBL2957427 0.93 ABCB11 (0.65) KDRFLT4PDGFRBTEKAURKB
SCHEMBL4384520 0.92 SRC (0.60) KDRFLT4PDGFRBTEKAURKB
SCHEMBL4375714 0.88 KDR (0.62) KDRFLT4PDGFRBTEKAURKB
SCHEMBL3193278 0.86 KDR (0.69) KDRFLT4PDGFRBTEKAURKB
SCHEMBL4378567 0.86 ABCB11 (0.64) KDRFLT4PDGFRBTEKAURKB
SCHEMBL2958541 0.86 EGFR (0.54) KDRFLT4PDGFRBTEKAURKB
SCHEMBL11953087 0.84 KDR (0.55) KDRFLT4PDGFRBTEKAURKB
SCHEMBL4374025 0.84 KDR (0.56) KDRFLT4PDGFRBTEKAURKB
SCHEMBL4378590 0.83 ABCB11 (0.60) KDRFLT4PDGFRBTEKAURKB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8492560-B2 Quinazoline derivatives as angiogenesis inhibitors ASTRAZENECA AB (SE) 2013-07-23 US disclosed
US-20120197027-A1 Quinazoline Derivatives as Angiogenesis Inhibitors STOKES ELAINE S E (GB) 2012-08-02 US disclosed
EP-2050744-A1 Quinazoline derivatives as angiogenesis inhibitors AstraZeneca AB (SE) 2009-04-22 EP disclosed
US-7074800-B1 Quinazoline derivatives as angiogenesis inhibitors ASTRAZENECA AB (SE) 2006-07-11 US disclosed
US-20060004017-A1 Quinazoline derivatives as angiogenesis inhibitors ASTRAZENECA AB 2006-01-05 US disclosed
EP-1553097-A1 QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS AND INTERMEDIATES THEREFORE AstraZeneca AB (SE) 2005-07-13 EP disclosed
EP-1154774-B1 QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS ASTRAZENECA AB (SE) 2005-06-22 EP disclosed
EP-1154774-A1 QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS AstraZeneca AB (SE) 2001-11-21 EP disclosed
WO-2000047212-A1 QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS ASTRAZENECA AB (SE) 2000-08-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120197027-A1 Quinazoline Derivatives as Angiogenesis Inhibitors VEGFA, FLT1, KDR KDR 3/4885FLT4 4/4885PDGFRB 125/4885
US-20060004017-A1 Quinazoline derivatives as angiogenesis inhibitors FLT4, NOS3, FLT1 KDR 4/4885FLT4 1/4885PDGFRB 160/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.